INVO FERTILITY INC (IVF) Fundamental Analysis & Valuation

NASDAQ:IVF • US44984F8077

Current stock price

2.51 USD
-0.1 (-3.83%)
At close:
2.41 USD
-0.1 (-3.98%)
After Hours:

This IVF fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. IVF Profitability Analysis

1.1 Basic Checks

  • IVF had negative earnings in the past year.
  • IVF had a negative operating cash flow in the past year.
  • IVF had negative earnings in each of the past 5 years.
  • In the past 5 years IVF always reported negative operating cash flow.
IVF Yearly Net Income VS EBIT VS OCF VS FCFIVF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M -10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -155.09%, IVF is doing worse than 87.77% of the companies in the same industry.
  • IVF's Return On Equity of -499.38% is on the low side compared to the rest of the industry. IVF is outperformed by 83.51% of its industry peers.
Industry RankSector Rank
ROA -155.09%
ROE -499.38%
ROIC N/A
ROA(3y)-109.72%
ROA(5y)-93.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IVF Yearly ROA, ROE, ROICIVF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

  • IVF has a worse Gross Margin (39.17%) than 67.02% of its industry peers.
  • In the last couple of years the Gross Margin of IVF has declined.
  • IVF does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.07%
GM growth 5Y-13.44%
IVF Yearly Profit, Operating, Gross MarginsIVF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. IVF Health Analysis

2.1 Basic Checks

  • IVF does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, IVF has more shares outstanding
  • Compared to 5 years ago, IVF has more shares outstanding
  • IVF has a worse debt/assets ratio than last year.
IVF Yearly Shares OutstandingIVF Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500 1K 1.5K 2K
IVF Yearly Total Debt VS Total AssetsIVF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -7.87, we must say that IVF is in the distress zone and has some risk of bankruptcy.
  • IVF has a worse Altman-Z score (-7.87) than 77.13% of its industry peers.
  • A Debt/Equity ratio of 0.31 indicates that IVF is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.31, IVF perfoms like the industry average, outperforming 50.53% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z -7.87
ROIC/WACCN/A
WACC9.96%
IVF Yearly LT Debt VS Equity VS FCFIVF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M 20M

2.3 Liquidity

  • A Current Ratio of 0.12 indicates that IVF may have some problems paying its short term obligations.
  • IVF's Current ratio of 0.12 is on the low side compared to the rest of the industry. IVF is outperformed by 94.15% of its industry peers.
  • IVF has a Quick Ratio of 0.12. This is a bad value and indicates that IVF is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.10, IVF is doing worse than 94.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.12
Quick Ratio 0.1
IVF Yearly Current Assets VS Current LiabilitesIVF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. IVF Growth Analysis

3.1 Past

  • IVF shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -275.94%.
  • IVF shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.50%.
  • The Revenue has been growing by 34.57% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-275.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.92%
Revenue 1Y (TTM)11.5%
Revenue growth 3Y16.23%
Revenue growth 5Y34.57%
Sales Q2Q%22.8%

3.2 Future

  • IVF is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.93% yearly.
  • The Revenue is expected to grow by 43.80% on average over the next years. This is a very strong growth
EPS Next Y92.01%
EPS Next 2Y41.37%
EPS Next 3Y25.98%
EPS Next 5Y14.93%
Revenue Next Year13.23%
Revenue Next 2Y28.14%
Revenue Next 3Y37.4%
Revenue Next 5Y43.8%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IVF Yearly Revenue VS EstimatesIVF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20M 40M 60M 80M
IVF Yearly EPS VS EstimatesIVF Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -1K -2K -3K -4K -5K

More info and screens

Find the best growth stocksShow best growing peers

1

4. IVF Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IVF. In the last year negative earnings were reported.
  • Also next year IVF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IVF Price Earnings VS Forward Price EarningsIVF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IVF Per share dataIVF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1K -2K -3K

4.3 Compensation for Growth

  • IVF's earnings are expected to grow with 25.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.37%
EPS Next 3Y25.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IVF Dividend Analysis

5.1 Amount

  • No dividends for IVF!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IVF Fundamentals: All Metrics, Ratios and Statistics

INVO FERTILITY INC

NASDAQ:IVF (4/2/2026, 8:00:02 PM)

After market: 2.41 -0.1 (-3.98%)

2.51

-0.1 (-3.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-17
Earnings (Next)04-28
Inst Owners9.47%
Inst Owner Change-100%
Ins Owners0%
Ins Owner Change-0.69%
Market Cap17.47M
Revenue(TTM)6.94M
Net Income(TTM)-29.21M
Analysts80
Price TargetN/A
Short Float %N/A
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.08%
Min Revenue beat(2)-3.98%
Max Revenue beat(2)10.15%
Revenue beat(4)3
Avg Revenue beat(4)60.92%
Min Revenue beat(4)-3.98%
Max Revenue beat(4)236.57%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-97.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1000%
EPS NY rev (1m)-11.52%
EPS NY rev (3m)-11.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.52
P/FCF N/A
P/OCF N/A
P/B 2.99
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3200.33
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS1
BVpS0.84
TBVpS-0.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -155.09%
ROE -499.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.17%
FCFM N/A
ROA(3y)-109.72%
ROA(5y)-93.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.07%
GM growth 5Y-13.44%
F-Score3
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.3%
Cap/Sales 1.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.12
Quick Ratio 0.1
Altman-Z -7.87
F-Score3
WACC9.96%
ROIC/WACCN/A
Cap/Depr(3y)84.61%
Cap/Depr(5y)530.77%
Cap/Sales(3y)6.25%
Cap/Sales(5y)7.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-275.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.92%
EPS Next Y92.01%
EPS Next 2Y41.37%
EPS Next 3Y25.98%
EPS Next 5Y14.93%
Revenue 1Y (TTM)11.5%
Revenue growth 3Y16.23%
Revenue growth 5Y34.57%
Sales Q2Q%22.8%
Revenue Next Year13.23%
Revenue Next 2Y28.14%
Revenue Next 3Y37.4%
Revenue Next 5Y43.8%
EBIT growth 1Y-61.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.63%
EBIT Next 3Y27.17%
EBIT Next 5Y32.46%
FCF growth 1Y-43.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.93%
OCF growth 3YN/A
OCF growth 5YN/A

INVO FERTILITY INC / IVF Fundamental Analysis FAQ

What is the ChartMill fundamental rating of INVO FERTILITY INC (IVF) stock?

ChartMill assigns a fundamental rating of 2 / 10 to IVF.


What is the valuation status of INVO FERTILITY INC (IVF) stock?

ChartMill assigns a valuation rating of 1 / 10 to INVO FERTILITY INC (IVF). This can be considered as Overvalued.


Can you provide the profitability details for INVO FERTILITY INC?

INVO FERTILITY INC (IVF) has a profitability rating of 0 / 10.


How financially healthy is INVO FERTILITY INC?

The financial health rating of INVO FERTILITY INC (IVF) is 1 / 10.


Can you provide the expected EPS growth for IVF stock?

The Earnings per Share (EPS) of INVO FERTILITY INC (IVF) is expected to grow by 92.01% in the next year.